S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This partially randomized phase I/II trial studies the side effects and best dose of
pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination
chemotherapy and to see how well they work compared with combination chemotherapy alone in
treating patients with newly diagnosed pancreatic cancer that has spread to other places in
the body. Pegylated recombinant human hyaluronidase may help chemotherapy drugs work better
by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as
leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether
combination chemotherapy is more effective with or without pegylated recombinant human
hyaluronidase in treating pancreatic cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Halozyme Therapeutics National Cancer Institute (NCI)